← Leaderboards
Ronald G Crystal
Weill Medical College Of Cornell Univ
$80,684,359
Attributed
$92,042,711
Total exposure
69
Grants
46
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$152,922,573 · 75
By mechanism
U01$41,851,662 · 9
R01$34,608,658 · 14
P01$25,293,711 · 4
P50$20,939,427 · 8
R33$8,389,972 · 2
P20$5,296,938 · 1
Top collaborators
- Jason G Mezey9 shared
- Steven S Gross5 shared
- Stephen Michael Kaminsky4 shared
- Jonathan W. Weinsaft4 shared
- Douglas J Ballon3 shared
- Robert J Kaner3 shared
- Stefan Worgall2 shared
- Karen Kozarsky1 shared
Most similar at Weill Medical College Of Cornell Univ
Same institution · by research overlap
- Nicholas D Schiff$5,330,381
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseClinical ResearchGene TherapyGene ExpressionPhenotypeLungCellsLinkTransfection /Expression VectorSmokingMediatingGenesSmokerPreventSerotypingCigarette SmokingIn VitroProteinsNon-SmokerPathogenesisCodeChronic Obstructive Airway DiseaseAirway EpitheliumTechnology
Grant awards (198)
Gene Therapy for Alpha 1-Antitrypsin Deficiency$2,505,334
R33 · FY2025 · HL · contact PI
Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency in Post-menopausal East Asian Women$1,253,597
R42 · FY2025 · AA · contact PI
Ancillary SOURCE Study: Characterization of Small Airway Basal Cell Biology in Early COPD$803,355
R01 · FY2025 · HL · contact PI
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia$1,380,330
R33 · FY2024 · HL · contact PI
Ancillary SOURCE Study: Characterization of Small Airway Basal Cell Biology in Early COPD$787,290
R01 · FY2024 · HL · contact PI
Gene Therapy for Alpha 1-Antitrypsin Deficiency$422,895
R61 · FY2024 · HL · contact PI
Gene Therapy-mediated Angiogenesis to Enhance Survival of Transplanted Fat$295,901
R41 · FY2024 · HL · contact PI
Safety of AAV-mediated C1 Esterase Inhibitor Gene Therapy for Hereditary Angioedema$275,737
R41 · FY2024 · AI · contact PI
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia$2,104,654
R33 · FY2023 · HL · contact PI
Ancillary SOURCE Study: Characterization of Small Airway Basal Cell Biology in Early COPD$799,965
R01 · FY2023 · HL · contact PI
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia$2,399,654
R33 · FY2022 · HL · contact PI
Anti-eosinophil Gene Therapy for Eosinophilic Esophagitis$300,000
R41 · FY2022 · AI · contact PI
Rapid Noninvasive Whole-body Imaging of AAV Gene Transfer Vectors$672,237
R01 · FY2021 · EB · contact PI
Rapid Noninvasive Whole-body Imaging of AAV Gene Transfer Vectors$688,434
R01 · FY2020 · EB
Clinical Assessment of Anti-cocaine Vaccine dAdGNE in Cocaine Addicts$534,128
U01 · FY2020 · DA · contact PI
CNS Gene Therapy for CLN2 Disease Using Parallel Multiple Routes of Administration$499,916
R41 · FY2020 · NS · contact PI
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia$420,378
R61 · FY2020 · HL · contact PI
Oxidation-resistant Anti-protease Therapy$341,571
R42 · FY2020 · HL · contact PI
Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency$252,042
R41 · FY2020 · AA · contact PI
Oxidation-resistant Anti-protease Therapy$1,157,532
R42 · FY2019 · HL · contact PI
HIV Reprogrammed Airway Basal Cells Acquire a âTissue Destructiveâ Phenotype$838,744
R01 · FY2019 · HL · contact PI
Rapid Noninvasive Whole-body Imaging of AAV Gene Transfer Vectors$686,741
R01 · FY2019 · EB · contact PI
Clinical Assessment of Anti-cocaine Vaccine dAdGNE in Cocaine Addicts$539,718
U01 · FY2019 · DA · contact PI
Gene Therapy to Prevent Esophageal Cancer Associated with Aldehyde Dehydrogenase Deficiency$224,970
R41 · FY2019 · AA · contact PI
Gene Therapy to Protect the Lung from Oxidant Stress$224,593
R41 · FY2019 · HL · contact PI
Pulmonary Genetic Medicine Training Program$84,647
T32 · FY2019 · HL · contact PI
HIV Reprogrammed Airway Basal Cells Acquire a âTissue Destructiveâ Phenotype$838,744
R01 · FY2018 · HL · contact PI
In Vivo Biomarker that Identifies Waterpipe Smoking-related Lung Health$508,500
R01 · FY2018 · HL · contact PI
Pulmonary Genetic Medicine Training Program$393,530
T32 · FY2018 · HL · contact PI
Oxidation-resistant Anti-protease Therapy$224,967
R42 · FY2018 · HL · contact PI
Integrative-omics Network Model of the Disordered COPD Small Airway Epithelium$984,610
R01 · FY2017 · HL · contact PI
HIV Reprogrammed Airway Basal Cells Acquire a âTissue Destructiveâ Phenotype$834,313
R01 · FY2017 · HL · contact PI
HIV-related Accelerated Aging of the Airway Epithelium$793,263
R01 · FY2017 · HL · contact PI
HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium$744,905
U01 · FY2017 · HL · contact PI
In Vivo Biomarker that Identifies Waterpipe Smoking-related Lung Health$508,500
R01 · FY2017 · HL · contact PI
Biology of the Oral Epithelium of E-Cigarette Smokers$254,250
R56 · FY2017 · DE · contact PI
Pulmonary Genetic Medicine Training Program$208,033
T32 · FY2017 · HL · contact PI
Pulmonary Genetic Medicine Training Program$10,157
T32 · FY2017 · HL · contact PI
Integrative-omics Network Model of the Disordered COPD Small Airway Epithelium$993,278
R01 · FY2016 · HL · contact PI
HIV Reprogrammed Airway Basal Cells Acquire a âTissue Destructiveâ Phenotype$838,744
R01 · FY2016 · HL · contact PI
HIV-related Accelerated Aging of the Airway Epithelium$804,376
R01 · FY2016 · HL · contact PI
Second-generation Gene Transfer Vector-based Anti-cocaine Vaccines$786,533
R01 · FY2016 · DA · contact PI
COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function$760,500
P20 · FY2016 · HL · contact PI
HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium$744,905
U01 · FY2016 · HL · contact PI
In Vivo Biomarker that Identifies Waterpipe Smoking-related Lung Health$508,500
R01 · FY2016 · HL · contact PI
Pulmonary Genetic Medicine Training Program$296,446
T32 · FY2016 · HL · contact PI
Biology of the Oral Epithelium of E-Cigarette Smokers$254,250
R56 · FY2016 · DE · contact PI
COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function$1,252,896
P20 · FY2015 · HL · contact PI
Integrative-omics Network Model of the Disordered COPD Small Airway Epithelium$944,986
R01 · FY2015 · HL · contact PI
HIV-related Accelerated Aging of the Airway Epithelium$802,906
R01 · FY2015 · HL · contact PI
Second-generation Gene Transfer Vector-based Anti-cocaine Vaccines$782,559
R01 · FY2015 · DA · contact PI
HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium$744,905
U01 · FY2015 · HL · contact PI
Pulmonary Genetic Medicine Training Program$375,101
T32 · FY2015 · HL · contact PI
Disrupted Adenovirus Serotype 5-based Anti-cocaine Vaccine$2,210,393
U01 · FY2014 · DA · contact PI
Gene Therapy for Metachromatic Leukodystrophy$1,598,287
U01 · FY2014 · NS · contact PI
COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function$1,252,896
P20 · FY2014 · HL · contact PI
Overlapping Airway Basal Cell Transcriptome Reprogramming in COPD and Lung Cancer$1,039,556
R01 · FY2014 · HL · contact PI
Integrative-omics Network Model of the Disordered COPD Small Airway Epithelium$927,173
R01 · FY2014 · HL · contact PI
Second-generation Gene Transfer Vector-based Anti-cocaine Vaccines$794,477
R01 · FY2014 · DA · contact PI
HIV-related Accelerated Aging of the Airway Epithelium$786,575
R01 · FY2014 · HL · contact PI
HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium$730,008
U01 · FY2014 · HL · contact PI
Management Project - Gene Therapy for Metachromatic Leukodystrophy$157,373
U01 · FY2014 · NS · contact PI
Disrupted Adenovirus Serotype 5-based Anti-cocaine Vaccine$2,528,781
U01 · FY2013 · DA · contact PI
COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function$1,270,146
P20 · FY2013 · HL · contact PI
Overlapping Airway Basal Cell Transcriptome Reprogramming in COPD and Lung Cancer$985,692
R01 · FY2013 · HL · contact PI
Gene Therapy for Batten Disease Using AAVrh.10 Expressing Human CLN2 cDNA$951,786
R01 · FY2013 · NS · contact PI
Overlapping Airway Basal Cell Transcriptome Reprogramming in COPD and Lung Cancer$834,931
R01 · FY2013 · HL · contact PI
Second-generation Gene Transfer Vector-based Anti-cocaine Vaccines$811,852
R01 · FY2013 · DA · contact PI
HIV-related Accelerated Aging of the Airway Epithelium$763,466
R01 · FY2013 · HL · contact PI
HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium$709,149
U01 · FY2013 · HL · contact PI
Pulmonary Genetic Medicine Training Program$273,183
T32 · FY2013 · HL · contact PI
Genetically-delivered Bevacizumab for Treatment of Wet Age-Related Macular Degene$261,327
R43 · FY2013 · EY
Disrupted Adenovirus Serotype 5-based Anti-cocaine Vaccine$2,868,677
U01 · FY2012 · DA · contact PI
Gene Therapy for Metachromatic Leukodystrophy$1,623,960
U01 · FY2012 · NS · contact PI
Overlapping Airway Basal Cell Transcriptome Reprogramming in COPD and Lung Cancer$1,028,637
R01 · FY2012 · HL · contact PI
Gene Therapy for Batten Disease Using AAVrh.10 Expressing Human CLN2 cDNA$938,618
R01 · FY2012 · NS · contact PI
Overlapping Airway Basal Cell Transcriptome Reprogramming in COPD and Lung Cancer$834,931
R01 · FY2012 · HL · contact PI
COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function$760,500
P20 · FY2012 · HL · contact PI
Pulmonary Genetic Medicine Training Program$352,655
T32 · FY2012 · HL · contact PI
Management Project - Gene Therapy for Metachromatic Leukodystrophy$156,447
U01 · FY2012 · NS · contact PI
Disarray of Injury/Regeneration Homeostasis in Smoking-Induced COPD$2,845,910
P50 · FY2011 · HL · contact PI
Gene Therapy for Metachromatic Leukodystrophy$1,647,750
U01 · FY2011 · NS · contact PI
Overlapping Airway Basal Cell Transcriptome Reprogramming in COPD and Lung Cancer$1,028,637
R01 · FY2011 · HL · contact PI
Gene Therapy for Batten Disease Using AAVrh.10 Expressing Human CLN2 cDNA$926,056
R01 · FY2011 · NS · contact PI
Dysregulation of Ciliogenesis in the Ariway Epithelium in COPD$403,444
P50 · FY2011 · HL · contact PI
Pulmonary Genetic Medicine Training Program$351,307
T32 · FY2011 · HL · contact PI
Management Project - Gene Therapy for Metachromatic Leukodystrophy$155,385
U01 · FY2011 · NS · contact PI
Administration$134,501
P50 · FY2011 · HL · contact PI
Disarray of Injury/Regeneration Homeostasis in Smoking-Induced COPD$2,845,883
P50 · FY2010 · HL · contact PI
Adenovirus-based Anti-Cocaine Vaccine$1,894,063
RC2 · FY2010 · DA · contact PI
Gene Therapy for Batten Disease Using AAVrh.10 Expressing Human CLN2 cDNA$900,949
R01 · FY2010 · NS · contact PI
Dysregulation of Ciliogenesis in the Ariway Epithelium in COPD$403,444
P50 · FY2010 · HL · contact PI
Adenovirus-based Nanoparticle Vaccines$401,128
R01 · FY2010 · DA · contact PI
Pulmonary Genetic Medicine Training Program$345,786
T32 · FY2010 · HL · contact PI
Administration$134,474
P50 · FY2010 · HL · contact PI
Assessment of Neurological Deterioration in Subjects with LINCL$81,310
U54 · FY2010 · NS · contact PI
Disarray of Injury/Regeneration Homeostasis in Smoking-Induced COPD$2,845,858
P50 · FY2009 · HL · contact PI
Adenovirus-based Anti-Cocaine Vaccine$1,946,312
RC2 · FY2009 · DA · contact PI
Gene Therapy for Batten Disease$1,549,439
U01 · FY2009 · NS · contact PI
Dysregulation of Ciliogenesis in the Ariway Epithelium in COPD$403,444
P50 · FY2009 · HL · contact PI
Adenovirus-based Nanoparticle Vaccines$380,250
R01 · FY2009 · DA · contact PI
Pulmonary Genetic Medicine Training Program$342,935
T32 · FY2009 · HL · contact PI
Administration$134,449
P50 · FY2009 · HL · contact PI
Assessment of Neurological Deterioration in Subjects with LINCL$82,949
U54 · FY2009 · NS · contact PI
Disarray of Injury/Regeneration Homeostasis in Smoking-Induced COPD$2,788,914
P50 · FY2008 · HL · contact PI
Gene Therapy for Cystic Fibrosis$2,403,656
P01 · FY2008 · HL · contact PI
Gene Therapy for Batten Disease$1,601,406
U01 · FY2008 · NS · contact PI
Vaccine Platforms$976,949
U54 · FY2008 · AI · contact PI
Dysregulation of Ciliogenesis in the Ariway Epithelium in COPD$403,444
P50 · FY2008 · HL · contact PI
Administration$134,422
P50 · FY2008 · HL · contact PI
Disarray of Injury/Regeneration Homeostasis in Smoking-Induced COPD$2,845,807
P50 · FY2007 · HL · contact PI
Gene Therapy for Cystic Fibrosis$2,384,333
P01 · FY2007 · HL · contact PI
Gene Therapy for Batten Disease$1,601,368
U01 · FY2007 · NS · contact PI
Candidate Genes for Susceptibility to Bronchitis$577,098
R01 · FY2007 · HL · contact PI
Dysregulation of Ciliogenesis in the Ariway Epithelium in COPD$403,444
P50 · FY2007 · HL · contact PI
Administration$134,398
P50 · FY2007 · HL · contact PI
EVALUATION OF NORMALS/ BRONCHOPULMONARY LUNG LAVAGE/ BRONCHIAL BRUSHING ETC$23,503
M01 · FY2007 · RR · contact PI
EVALUATION OF AIRWAYS OF INDIVIDUALS WITH LUNG DISEASE$16,984
M01 · FY2007 · RR · contact PI
GENE TRANSFER VECTOR HUMAN CLN2 CDNA BRAIN OF CHILDREN LINCL$1,778
M01 · FY2007 · RR · contact PI
GENOTYPE-PHENOTYPE OF LINCL$355
M01 · FY2007 · RR · contact PI
Gene Therapy for Cystic Fibrosis$2,387,170
P01 · FY2006 · HL · contact PI
Gene Therapy for Batten Disease$1,431,192
U01 · FY2006 · NS · contact PI
Candidate Genes for Susceptibility to Bronchitis$600,973
R01 · FY2006 · HL · contact PI
EVALUATION OF NORMALS/ BRONCHOPULMONARY LUNG LAVAGE/ BRONCHIAL BRUSHING ETC$500,732
M01 · FY2006 · RR · contact PI
Manipulation of VEGF splicing in angiogenic gene therapy$290,389
P01 · FY2006 · HL · contact PI
GENE TRANSFER VECTOR HUMAN CLN2 CDNA BRAIN OF CHILDREN LINCL$202,561
M01 · FY2006 · RR · contact PI
EVALUATION OF AIRWAYS OF INDIVIDUALS WITH LUNG DISEASE$158,808
M01 · FY2006 · RR · contact PI
GENOTYPE-PHENOTYPE OF LINCL$48,615
M01 · FY2006 · RR · contact PI
Weill Cornell Program of Excellence in Gene Therapy$2,545,982
U01 · FY2005 · HL
Gene Therapy for Cystic Fibrosis$2,376,646
P01 · FY2005 · HL
Gene Therapy for Batten Disease$1,435,327
U01 · FY2005 · NS
Candidate Genes for Susceptibility to Bronchitis$616,859
R01 · FY2005 · HL
Manipulation of VEGF splicing in angiogenic gene therapy$290,389
P01 · FY2005 · HL
EVALUATION OF NORMALS/ BRONCHOPULMONARY LUNG LAVAGE/ BRONCHIAL BRUSHING ETC$166,892
M01 · FY2005 · RR
GENOTYPE-PHENOTYPE OF LINCL$68,506
M01 · FY2005 · RR
GENE TRANSFER VECTOR HUMAN CLN2 CDNA BRAIN OF CHILDREN LINCL$67,777
M01 · FY2005 · RR
EVALUATION OF AIRWAYS OF INDIVIDUALS WITH LUNG DISEASE$43,727
M01 · FY2005 · RR
WEILL CORNELL PROGRAM OF EXCELLENCE IN GENE THERAPY$2,739,199
U01 · FY2004 · HL
Gene Therapy for Cystic Fibrosis$2,359,249
P01 · FY2004 · HL
Candidate Genes for Susceptibility to Bronchitis$618,395
R01 · FY2004 · HL
Manipulation of VEGF splicing in angiogenic gene therapy$290,389
P01 · FY2004 · HL
EVALUATION OF NORMALS/ BRONCHOPULMONARY LUNG LAVAGE/ BRONCHIAL BRUSHING ETC$55,953
M01 · FY2004 · RR
EVALUATION OF AIRWAYS OF INDIVIDUALS WITH LUNG DISEASE$29,575
M01 · FY2004 · RR
WEILL CORNELL PROGRAM OF EXCELLENCE IN GENE THERAPY$2,636,978
U01 · FY2003 · HL
Gene Transfer to Progenitor and Differentiated Cells$2,193,235
P01 · FY2003 · HL
GENE THERAPY FOR CYSTIC FIBROSIS$1,886,945
P01 · FY2003 · HL
Manipulation of VEGF splicing in angiogenic gene therapy$290,389
P01 · FY2003 · HL
Anti-Y. pestis Vaccination and Passive Protection$254,252
R01 · FY2003 · AI
WEILL CORNELL PROGRAM OF EXCELLENCE IN GENE THERAPY$2,439,199
U01 · FY2002 · HL
Gene Transfer to Progenitor and Differentiated Cells$2,134,354
P01 · FY2002 · HL
GENE THERAPY FOR CYSTIC FIBROSIS$1,837,982
P01 · FY2002 · HL
Manipulation of VEGF splicing in angiogenic gene therapy$290,389
P01 · FY2002 · HL
SHH INDUCTION OF POST-NATAL HAIR FOLLICLE/HAIR GROWTH$277,521
R01 · FY2002 · AR
T CELL INDEPENDENT ANTIPSEUDOMONAS VACCINE DEVELOPMENT$199,380
U01 · FY2002 · HL
EVALUATION OF THE AIRWAYS OF NORMAL INDIVIDUALS WITH BRONCHOPULMONARY LAVAGE$0
M01 · FY2002 · RR
UNIDIRECTIONAL TRAFFICKING OF ADENOVIRUS VECTORS$0
P01 · FY2002 · HL
IMMUNE RESPONSE TO ADENOVIRUS TYPE 5 GENE TRANSFER VECTOR$0
M01 · FY2002 · RR
REPEAT ADMIN OF REPLICATION DEFICIENT ADENOVIRUS VECTOR IN CYSTIC FIBROSI$0
M01 · FY2002 · RR
WEILL CORNELL PROGRAM OF EXCELLENCE IN GENE THERAPY$2,739,199
U01 · FY2001 · HL
GENE THERAPY FOR CYSTIC FIBROSIS$1,836,597
P01 · FY2001 · HL
GENE TRANSFER TO PROGENITOR AND DIFFERENTIATED CELLS$1,134,743
P50 · FY2001 · HL
REGIONAL ANGIOGENESIS INDUCED BY IN VIVO GENE THERAPY$286,478
R01 · FY2001 · HL
CORE--MOLECULAR BIOLOGY/GENE TRANSFER$280,718
P50 · FY2001 · HL
REGIONAL INDUCTION OF ANGIOGENESIS BY IN VIVO GENE TRANSFER$280,718
P50 · FY2001 · HL
SHH INDUCTION OF POST-NATAL HAIR FOLLICLE/HAIR GROWTH$278,828
R01 · FY2001 · AR
T CELL INDEPENDENT ANTIPSEUDOMONAS VACCINE DEVELOPMENT$199,380
U01 · FY2001 · HL
CORE--PILOT PROJECTS$126,320
P50 · FY2001 · HL
GENE TRANSFER TO ALVEOLAR MACROPHAGES$126,320
P50 · FY2001 · HL
PEGT Coordinating and Data Core at Weill Cornell$48,138
U01 · FY2001 · HL
DIRECT ADMIN /ADENOVIRIDAE VECTOR W/VEGF121/ CDNA TO LOWER ISCHEMIC LIMB$0
M01 · FY2001 · RR
UNIDIRECTIONAL TRAFFICKING OF ADENOVIRUS VECTORS$0
P01 · FY2001 · HL
IMMUNE RESPONSE TO ADENOVIRUS TYPE 5 GENE TRANSFER VECTOR$0
M01 · FY2001 · RR
REPEAT ADMIN OF REPLICATION DEFICIENT ADENOVIRUS VECTOR IN CYSTIC FIBROSI$0
M01 · FY2001 · RR
EVALUATION OF THE AIRWAYS OF NORMAL INDIVIDUALS WITH BRONCHOPULMONARY LAVAGE$0
M01 · FY2001 · RR
VEGF VECTOR TO ISCHEMIC MYOCARDIUM W/DIFFUSE CORONARY DISEASE$0
M01 · FY2001 · RR
DIRECT ADMINISTRATIONOF ADGVVEGF121.10 W/VEGF121CDNA TO ISCH MYOCARADIUM$0
M01 · FY2001 · RR
EVALUATION OF AIRWAYS OF NORMAL INDIVIDUALS$0
M01 · FY2001 · RR
WEILL CORNELL PROGRAM OF EXCELLENCE IN GENE THERAPY$2,791,324
U01 · FY2000 · HL
GENE THERAPY FOR CYSTIC FIBROSIS$1,789,000
P01 · FY2000 · HL
GENE TRANSFER TO PROGENITOR AND DIFFERENTIATED CELLS$1,221,702
P50 · FY2000 · HL
CORE--PILOT PROJECTS$287,678
P50 · FY2000 · HL
GENE TRANSFER TO ALVEOLAR MACROPHAGES$287,678
P50 · FY2000 · HL
SHH INDUCTION OF POST-NATAL HAIR FOLLICLE/HAIR GROWTH$278,828
R01 · FY2000 · AR
REGIONAL ANGIOGENESIS INDUCED BY IN VIVO GENE THERAPY$278,134
R01 · FY2000 · HL
UNIDIRECTIONAL TRAFFICKING OF ADENOVIRUS VECTORS$252,599
P01 · FY2000 · HL
T CELL INDEPENDENT ANTIPSEUDOMONAS VACCINE DEVELOPMENT$199,380
U01 · FY2000 · HL
CORE--MOLECULAR BIOLOGY/GENE TRANSFER$165,857
P50 · FY2000 · HL
REGIONAL INDUCTION OF ANGIOGENESIS BY IN VIVO GENE TRANSFER$165,857
P50 · FY2000 · HL
EVALUATION OF AIRWAYS OF NORMAL INDIVIDUALS$79,525
M01 · FY2000 · RR
DIRECT ADMIN /ADENOVIRIDAE VECTOR W/VEGF121/ CDNA TO LOWER ISCHEMIC LIMB$79,525
M01 · FY2000 · RR
DIRECT ADMINISTRATIONOF ADGVVEGF121.10 W/VEGF121CDNA TO ISCH MYOCARADIUM$79,525
M01 · FY2000 · RR
ADMINISTRATION OF NORMAL CDNA ADENOVIRUS VECTOR IN CYSTIC FIBROSIS$79,525
M01 · FY2000 · RR
PHASE 1 STUDY/ DIRECT ADMIN. ADENOVIRUS VECTOR/ E COLI CYTOSINE DEAMINASE GENE$79,525
M01 · FY2000 · RR
ADMIN. OF DIFFERENT SEROTYPES OF AD VECTORS W/HUMAN THROMBOPOIETIN CDNA$79,525
M01 · FY2000 · RR
IMMUNE RESPONSE TO ADENOVIRUS TYPE 5 GENE TRANSFER VECTOR$0
M01 · FY2000 · RR
REPEAT ADMIN OF REPLICATION DEFICIENT ADENOVIRUS VECTOR IN CYSTIC FIBROSI$0
M01 · FY2000 · RR
EVALUATION OF THE AIRWAYS OF NORMAL INDIVIDUALS WITH BRONCHOPULMONARY LAVAGE$0
M01 · FY2000 · RR
VEGF VECTOR TO ISCHEMIC MYOCARDIUM W/DIFFUSE CORONARY DISEASE$0
M01 · FY2000 · RR